ADPT
NASDAQ
$21.86
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Sector:
Healthcare
Industry:
Diagnostics & Research
Buy
Target: $22 (+0.64%)
Market Cap
$3.66B
Revenue 5Y CAGR
+20.57%
Free Cash Flow Yield
-0.81%
Beta (5Y)
1.70
Price Chart
Valuation
Market Cap$3.66B
P/S2.90
P/B15.86
Profitability
Total Revenue (TTM)$295M
Gross Profit (TTM)$129M
EBITDA-$32M
Profit Margin-28.3%
Operating Margin-27.1%
EPS-$0.32
Financial Health
Debt-to-Equity60.3%
Free Cash Flow Yield-0.81%
Growth & Risk
EPS 5Y CAGR-22.53%
Revenue 5Y CAGR+20.57%
FCF 5Y CAGR-32.32%
Beta (5Y)1.70
Sharpe Ratio1.35